Biography and Research Information
OverviewAI-generated summary
Lokesh Akana's research investigates strategies to enhance the effectiveness of cancer therapies, particularly radiotherapy and chemoradiotherapy. His work has focused on identifying molecular targets that can sensitize cancer cells to radiation, with recent publications examining the role of Cyclin-dependent kinase 1 (CDK1) in pancreatic cancer radiosensitivity and SETD2 in rectal cancer. Akana has explored targeting SETD2 in combination with radiotherapy for rectal cancer, with findings suggesting that SETD2 loss can predict response to chemoradiotherapy. His research also includes investigating the potential of methionine restriction to enhance rectal cancer radiosensitivity and protect the gut. Additionally, Akana has studied the inhibition of Tri-Methyl-Histone H3 (Lys27) as a novel strategy to improve radiosensitivity and predict treatment response in rectal cancer. He has collaborated with researchers including Henrique Rodrigues and Oscar Zuniga at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 1
- Publications: 8
- Citations: 6
Selected Publications
-
Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer (2025)
-
SETD2 Loss Predicts Response to Chemoradiotherapy in Rectal Cancer: Clinical Outcomes and Preclinical Validation in Orthotopic Models (2025)
-
Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction (2025)
-
Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1 (2024)
-
Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1 (2024)
-
Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer (2024)
-
Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy (2023)
Collaboration Network
Top Collaborators
Adam R. Wolfe
University of Arkansas for Medical Sciences (US)
8 shared publications
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
Showing 5 of 8 shared publications
Saaimatul Huq
University of Arkansas for Medical Sciences (US)
5 shared publications
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
- Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer
Henrique Rodrigues
University of Arkansas for Medical Sciences
4 shared publications
In database
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
- Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer
Oscar Zuniga
University of Arkansas for Medical Sciences
3 shared publications
In database
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
H. Rodrigues
2 shared publications
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
- SETD2 Loss Predicts Response to Chemoradiotherapy in Rectal Cancer: Clinical Outcomes and Preclinical Validation in Orthotopic Models
Henrique Rodrigues
University of Arkansas for Medical Sciences (US)
2 shared publications
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
Stetson Van Matre
University of Arkansas for Medical Sciences
2 shared publications
In database
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
Óscar Zúñiga
University of Arkansas for Medical Sciences
2 shared publications
In database
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
A.Z. Kesaria
University of Arkansas for Medical Sciences (US)
1 shared publication
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
Eric U. Yee
University of Arkansas for Medical Sciences
1 shared publication
In database
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
Daniel E. Eldridge
Medical University of South Carolina (US)
1 shared publication
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
Isabelle R. Miousse
University of Arkansas for Medical Sciences
1 shared publication
In database
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Sarita Garg
University of Arkansas for Medical Sciences
1 shared publication
In database
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Kimberly J. Krager
University of Arkansas for Medical Sciences
1 shared publication
In database
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
David N. Church
University of Arkansas for Medical Sciences
1 shared publication
In database
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Similar Researchers
Based on overlapping research topics
Henrique Rodrigues
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
Robin Eluvathingal
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
Beverly Word
National Center for Toxicological Research
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Stetson Van Matre
University of Central Arkansas
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
Oscar Zuniga
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
Felicia D. Allard
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Diet and metabolism studies